Kornimate/medical-research-clean huggingface dataset:
adjunctive probiotics in chronic periodontitis

Conditions: Chronic Periodontitis; Probiotics

Summary: this study will assess clinical and microbiological efficacy of probiotics and antibiotics in patients of chronic periodontitis as an adjunctive to scaling and root planing (srp) in reducing bacterial count and in improving clinical periodontal parameters over the period of 12 weeks.also the comparison between these adjunctives will be made for clinical assessment clinical periodontal parameters will be taken .these parameters plaque index (pi), gingival index (gi), clinical attachment loss (cal) and pocket probing depth (ppd) for microbiological assessment plaque sample will be taken, dna will be extracted and then sample will be processed through quantitative polymerase chain reaction (qpcr) for quantitative analysis of bacterial count of porphyromonas gingivalis.

in this clinical trial total 60 participants of clinically diagnosed chronic periodontitis will be recruited after taking a written consent for their approval. participants will be divided into 3 groups a, b and c through the process of randomization using a method of opaque sealed envelopes. a research assistant will be hired for the purpose of randomization and allocation concealment. all participants will be asked to pick an opaque envelope containing the details of treatment products. after randomization plaque sample will be obtained from the depth of periodontal pockets and all the clinical periodontal parameters will be recorded in every participant. then all the participants will undergo srp. after srp group a will be given antibiotics amoxicillin 500 milligrams (mg) for 3 times a day (tds) and metronidazole 400 milligrams (mg) for twice a day (bd) for 5 days. group b will be given probiotics lactobacillus reuteri 1.2 billion colony forming unit (cfu) sachets twice daily for swallowing with water for 12 weeks. group c will be given lactobacillus sachets of same amount and participant will be asked to mix it with little amount of water and apply it on teeth with the toothbrush twice daily after brushing with standard tooth paste for 12 weeks. patients will be recalled at the interval of 3, 6, 9 and 12 weeks for the recording of clinical periodontal parameters. after completion of trial plaque sample will be taken again from every participant and will be processed through qpcr to check bacterial count of porphyromonas gingivalis before and after treatment. whereas comparison between clinical periodontal parameters will be made at the interval of 0, 3, 6, 9, 12 weeks.

Eligibility criteria:
inclusion criteria: * patients with clinically diagnosed chronic periodontitis with a pocket depth of ≥4mm. * patients with age ≥30 years. exclusion criteria: * handicapped patients who are physically or mentally unable to maintain their oral hygiene. * pregnant and lactating females. * patients with habits of smoking, chewing tobacco and alcohol consumption. * patients on local or systemic antibiotic treatment. * patients with any systemic diseases. * patients with the history of any periodontal therapy within last 6 months. * patients undergoing orthodontic treatment.
anti-xa levels in critically ill patients receiving low-molecular-weight heparin for thromboprophylaxis in china

Conditions: Critically Ill; Anti-Xa

Summary: critically ill patients are at high risk to develop deep venous thrombosis. however, despite receiving of a standard dose of low-molecular-weight heparin（lmwh）, many patients still develop life-threatening embolism. the purpose of this study is to evaluate the anti-xa levels of different dosing regimens of lmwh in critically ill patients in china.


Eligibility criteria:
inclusion criteria: * adult critically ill patients exclusion criteria: * contraindication to use of lmwh. intracranial bleeding/stroke, hematoma or bleeding disorder. use heparin anticoagulant therapy
clinical and biologic effects of metformin in early stage breast cancer

Conditions: Breast Cancer

Summary: the study will be testing metformin in patients with breast cancer who are about to undergo surgery. patients will take metformin 3 times daily for about 2-3 weeks prior to their surgery date. it is hypothesized that metformin will reduce cell proliferation rates in tumour tissue.


Eligibility criteria:
inclusion criteria: 1. invasive t1-4 (if t1, ≥ 1cm), nx operable breast cancer confirmed on core biopsy 2. \< 70 years of age 3. breast surgery scheduled at least 2 weeks after study entry at one of the participating institutions (metformin will be started no more than 3 weeks prior to scheduled surgery) for the current breast cancer 4. patient and physician consent exclusion criteria: 1. on metformin for any reason during the preceding 4 weeks 2. recent (within 4 weeks) antiestrogen or estrogen therapy 3. prior or concurrent systemic neoadjuvant bc therapy of any type (chemotherapy, hormone therapy, biologic therapy) 4. known diabetes or baseline fasting glucose \> or = 7.0 mmol/l (specific treatment is required) 5. current or recent (within 4 weeks) use of drugs that may influence insulin or insulin sensitivity including oral corticosteroids, insulin sensitizers, exogenous insulin or oral hypoglycemic agents 6. serum creatinine above upper limit of normal for the institution 7. history of lactic or other metabolic acidosis 8. consumption of \> 3 alcoholic beverages per day (on average) 9. ast \> 1.5 times upper limit of normal for the institution 10. known hypersensitivity or allergy to metformin 11. current or past congestive heart failure 12. coagulopathy (including use of anti-coagulants) precluding biopsy 13. pregnancy or lactation within 3 months. 14. serious psychiatric illness * note: women with childbearing potential will be required to use an effective form of birth control (condom or other barrier method, tubal ligation or vasectomy - oral contraceptives are contra-indicated in breast cancer) and to have a negative pregnancy test prior to starting metformin.

Keywords: breast cancer metformin breast surgery
mobile phone radiation and brain rhythm in epileptic patients

Conditions: Epilepsy

Summary: this work is intended to assess the effect of -30 minutes- exposure to mobile-phone on the functions of the central nervous system (cns) in epileptic patients.

this work shows the effect of the 30 minutes mobile waves' radiation over the normal person brain activity (eeg) and cognition (p300) together with the effect over the unstable brain of the epileptic patients. exposure to mobile-phone radiation has been reported to increase the spectral power of electroencephalograms (eegs), particularly in the alpha band, during both the waking and sleeping states. the tendency toward electrical instability of the neural networks of epileptic patients suggests that these individuals may be especially sensitive to electromagnetic fields espcially mobile-phone radiation (mpr). the short-term effects of exposure to electromagnetic (em) fields on a number of cognitive variables such as memory, attention and speed of decision-making could be assedsed by p 300 latency and amplitude.

Eligibility criteria:
inclusion criteria: * both sexes * above 18 years * epileptic patients (regardless of whether symptomatic, idiopathic, focal or generalized) exclusion criteria: * age less than 18 years * chronic medical condition * epileptic fit in the last 48 hours

Keywords: epilepsy mobile phone
application of extended reality (xr)-assisted ct-guided localization of pulmonary nodules in thoracoscopic sublobar resection.

Conditions: Lung Cancers; Metaverse; Virtual Surgical Simulation; Extended Reality (XR)

Summary: reality (xr)-assisted ct-guided localization

with the widespread use of computed tomography (ct), lung nodules detected through screening have become increasingly smaller. these small nodules are often hidden within the lung parenchyma, making them difficult to visualize or palpate during surgery. as a result, nodule localization techniques have become critically important and are heavily relied upon by thoracic surgeons. currently, ct-guided localization is the standard approach; however, this requires patients to move between the ct suite, the ward, and the operating room, which is highly inconvenient. an alternative is the use of a one-stop hybrid operating room, which integrates imaging and surgery in a single space, but this solution is costly. this study aims to enroll 20 patients in a pilot investigation of using extended reality (xr)-guided localization in video-assisted thoracoscopic surgery (vats) for lung nodule resection. by leveraging current xr technologies, a digital twin model will be superimposed onto the patient's body. our team-developed virtual localization technique will then be used to mark the tumor site with dye, enabling surgeons to precisely excise the tumor with minimal tissue removal. if successful, this technology has the potential to replace traditional ct-guided or hybrid operating room localization, thereby reducing patient inconvenience and financial burden, and ultimately achieving a streamlined and cost-effective surgical workflow.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 80 who are scheduled to undergo lung nodule resection surgery. * patients with lung nodules smaller than 2 cm that require preoperative localization. * patients with lung nodules located in the outer one-third of the lung. exclusion criteria: * patients younger than 18 or older than 80 years. * patients requiring lobectomy. * patients who have not provided written informed consent. * vulnerable populations.

Keywords: metaverse virtual surgical simulation extended reality (xr) pulmonary nodules digital twin
antimicrobial susceptibility testing guided therapy versus empirical therapy for the rescue treatment of helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to assess efficacy of 14-day antimicrobial susceptibility test guided quadruple therapy for the rescue treatment of helicobacter pylori infection, then comparing it with 14-day personal medication history guided therapy to tell which one has a better performance in both efficacy and safety.

helicobacter pylori (h.pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathology, especially non-cardiac gastric cancer. strong evidence supports that h.pylori eradication is an effective approach to reduce the incidence of those pathological processes. antimicrobial susceptibility test can pick out sensitive drugs to kill helicobacter pylori, and reduce secondary drug resistance. but, there is a lack of high quality rct to compare its efficacy with empirical regimen in the rescue treatment. this study aims to assess the efficacy of 14-day antimicrobial susceptibility test guided quadruple therapy for the rescue treatment of helicobacter pylori infection. comparing this regimen with 14-day personal medication history guided therapy to tell which one is better in clinic practice. alterations in h.pylori assosicated dyspepsia and safety outcomes will also be evaluated.

Eligibility criteria:
inclusion criteria: patients aged 18-70 with h. pylori infection. patients with previous h. pylori eradication therapy for one or two times. exclusion criteria: patients unable or unwilling to receive gastroscopy; patients treated with h2-receptor antagonist, ppi, bismuth and antibiotics in the previous 4 weeks; patients with gastrectomy, acute gi bleeding and advanced gastric cancer; patients with known or suspected allergy to study medications; currently pregnant or lactating; inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.

Keywords: antimicrobial susceptibility testing rescue therapy
the effect of spinal flexion in the lateral decubitus position on the unilaterality during spinal anesthesia

Conditions: Spinal Anesthesia

Summary: for unilateral spinal block, spinal local anesthetics should take effect on the spinal nerves of one side. with full flexion of the spine, the cauda equina becomes tightened and hangs in the middle of the subarachnoid space. this study was performed to assess if flexion of the vertebral column facilitates unilateral spinal anesthesia.


Eligibility criteria:
inclusion criteria: * asa physical status ⅰ-ⅱ, scheduled for elective knee arthroscopy under spinal anesthesia exclusion criteria: * hemodynamically unstable patients * lumbar disease * patients with back pain
norepinephrine / vasopressin combination for resuscitation in septic shock

Conditions: Septic Shock; Acute Kidney Injury

Summary: although norepinephrine is commonly used and is the recommended agent for the treatment of hypotension in volume-resuscitated hyperdynamic septic shock, low doses of vasopressin may be added to norepinephrine to maintain arterial blood pressure in refractory septic shock and to decrease exposure to norepinephrine. the aim of the work is to compare the effect of norepinephrine alone and norepinephrine/vasopressin combination on hemodynamics and tissue perfusion in septic shock patients.

study which was performed on 90 adult of either sex in intensive care unit who developed septic shock.45 patients in each group according to the drugs used, by the single blind technique as the treating physician only is aware of the drugs used. group 1: patients received iv norepinephrine infusion starting with (0.1mcg/kg/min). group 2: patients received iv norepinephrine infusion (starting with (0.1 mcg/kg/min). +vasopressin infusion at the rate of (0.03 unit/min). a comparison was done between both groups as regard:hemodynamics,tissue perfusion, c-reactive protein (mg/l) ,wbc, urea (mg/dl),creatinine (mg/dl), ngal (neutrophil gelatinase associated lipocalin) (ng/ml). comparison was done at baseline, then every 6 hours for 48 h as regard hemodynamics and tissue perfusion, and at base line then, 24 h and 48 h as regard sepsis biomarkers and renal biomarkers.

Eligibility criteria:
inclusion criteria: * age \> 18 years of both sex exclusion criteria * patients with renal impairment (creatinine\>2mg/dl) * sever heart disease (ischemic/valvular) * peripheral vascular disease (e.g. raynaud's phenomenon)
comparison of diabetes patients - care trajectory versus convention

Conditions: Type 2 Diabetes

Summary: in belgium, various structures and reimbursement programs are in place for managing type 2 diabetes mellitus (t2dm). the diabetes care trajectory is primarily utilized for patients who require a maximum of two insulin injections per day. in contrast, patients needing multiple daily insulin injections are managed under a diabetes convention program. the diabetes care trajectory has been operational since 2009. however, unlike patients in the diabetes convention program, where the profile and quality of care are regularly audited, there is limited information available regarding the profile and outcomes of patients within the care trajectory. this retrospective study aims to compare the profiles, including complications and quality of care, of t2dm patients across both groups.

this retrospective study will collect data from t2dm patients enrolled in either the diabetes care trajectory or the diabetes convention program. the data gathered will encompass quality of care, clinical status, complications, and metabolic state. the profiles of these patient populations will be compared cross-sectionally for each year within the study period (2009-2024). additionally, a longitudinal analysis will be conducted to examine the evolution of these profiles over the entire study period. data will be extracted from electronic case records maintained at participating sites across belgium.

Eligibility criteria:
inclusion criteria: * followed in one of the nexushealth hospitals in belgium: https://www.nexuzhealth.com/en/why-nexuzhealth/patients/affiliated-healthcare-institutions * having being diagnosed with type 2 diabetes mellitus * followed in the diabetes care trajectory or in the diabetes convention (group b) in belgium exclusion criteria: no specific exclusion criteria
aveir™ leadless pacemaker (lp) united kingdom (uk) registry

Conditions: Bradycardia; Atrio-Ventricular Block; Syncope

Summary: this observational study will follow patients requiring implantation of leadless pacemaker for 5 years after implantation. the main goal is to evaluate the long term safety and efficacy of aveir™ leadless pacemaker device in the usual clinical settings within the uk national health service. in addition, the study will collect data to understand patient characteristics receiving this type of pacemaker.

aveir™ stimulator (abbott) obtained the approvals in july 2023 and started to be implanted in patients in europe. as a leadless pacemaker, the aveir™ leadless pacemaker (lp) does not need a connector, pacing lead, or pulse generator pocket. the lp is delivered percutaneously via the femoral vein through an aveir™ introducer and delivery catheter. aveir™ lp is intended to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation. the lp is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy to the target treatment group. the purpose of this study is to understand long term safety and performance characteristic of this device. in addition, the study will collect anonymous clinical data and characteristics of the patients chosen to be implanted with aveir™ leadless pacemaker in routine clinical practice in approved centres across the uk. six hundred patients will be recruited in up to 15 centres during 2 years recruitment period. they will be followed up for 5 years after implantation of the leadless pacemaker. investigators will record their age, sex, medical history, indications for receiving aveir™ and any complications related to the implantation procedure or the device itself. all the data will be collected in an anonymous format. patients will be followed up according to the standard of care in the national health care system.

Eligibility criteria:
inclusion criteria: 1. patient is intended to receive or was treated with a (aveir™) leadless transcatheter pacing 2. subject is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams; and 3. subject has been informed of the nature of the study, agrees to its provisions, and has provided a signed written informed consent, approved by the regional ethics committee (rec). exclusion criteria: 1. subject is not suitable for implantation of the leadless device according to the expert opinion of their cardiologist. 2. subject is not willing to comply with clinical investigation procedures and does not agree to return for all required follow-up visits, tests, and exams 3. subject has been informed of the nature of the study, but does not agree to its provisions, and has not provided a signed written informed consent, approved by the rec

Keywords: aveir leadless pacemaker
centralized pan-russian survey on the undertreatment of hypercholesterolemia

Conditions: Dyslipidaemia

Summary: the purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the ldl-c goals according to the all-russian scientific cardiology society guidelines/ the 4th joint european task force guidelines.


Eligibility criteria:
inclusion criteria: * subject must be 18 years of age or older of either gender or race. * subject must provide informed consent and comply with the survey procedures. * subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. exclusion criteria: * subjects who are unwilling or unable to provide informed consent

Keywords: dyslipidaemia ldl-c goals guidelines
lazertinib 160mg in egfr t790m nsclc

Conditions: Lung Cancer Stage IV; EGFR T790M

Summary: the lazertinib is currently approved as 2nd line t790m mutation-positive nsclc that failed from either 1st or 2nd generation egfr tki. the current recommended dosage is 240mg. based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.


Eligibility criteria:
inclusion criteria: * pathologically confirmed non-small cell lung cancer * patients in a palliative setting who is not applicable for the curative treatment * egfr mutation positive patients who received previous 1st or 2nd generation egfr tki * confirmed egfr t790m mutation after the previous egfr tki * available to receive lazertinib either as po or vis levine tube * willing to participate clinical trial * age over or equal to 19 * ecog ps 0 to 2 exclusion criteria: * previously received 3rd generation egfr tki * no clinical benefit is expected based on the investigator's decision * uncontrolled symptomatic cns metastases * uncontrolled systemic disease
safety and efficacy of cdb-2914 for emergency contraception

Conditions: Emergency Contraception

Summary: the purpose of this study is to assess the safety and efficacy of cdb-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.


Eligibility criteria:
inclusion criteria: * aged 18 years or more * menstruating women with regular menstrual cycle between 24 and 35 days and intra-individual variations less than or equal to 5 days * request emergency contraception between 48 hours and 120 hours after unprotected intercourse as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure * no current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since having stopped hormonal contraception * for women with a recent history of depo provera use, the most recent injection must have been at least 9 months before study entry and followed by at least one complete menstrual cycle (2 menses) * willing to not use hormonal methods of contraception until study completion * at least one complete menstrual cycle (2 menses) post delivery, miscarriage or abortion * able to provide informed consent in english * give voluntary, written informed consent, and agree to observe all study requirements (the subject needs to be available for follow-up over the next 6 weeks) * willing to abstain from further acts of unprotected intercourse during participation in the study and until pregnancy status has been ascertained exclusion criteria: * one or more acts of one unprotected intercourse more than 120 hours before requesting emergency contraception in the current cycle * all acts of unprotected intercourse (in the current cycle) within 48 hours of presentation * currently pregnant as confirmed by positive hsup test performed at screening * currently breast-feeding * current use of hormonal contraception * use of hormonal emergency contraception since last menstrual period * current use of iud * tubal ligation * partner with a vasectomy * unsure about the date of the last menstrual period * severe asthma insufficiently controlled by oral glucocorticoid * currently enrolled in any other trial of an investigational medicine